Season 4 - Ep4: The future of guidelines in an era of big data and AI - Exercise in hypertrophic cardiomyopathy

11 snips

Mar 5, 2026

Michael Papadakis, a sports cardiology expert on hypertrophic cardiomyopathy, and Kostas Koskinas, an interventional cardiologist who summarizes recent studies. They discuss AI and big data shaping guideline development and living, continuously updated recommendations. They cover individualized risk scores, EHR integration, and new, personalized advice on exercise for people with hypertrophic cardiomyopathy.

Ask episode

AI Snips

Chapters

Transcript

Episode notes

INSIGHT

Big Data Enables Truly Individualized Risk Scores

Big data will make risk scores far more precise and individualized.
Guidelines can use millions of patient records to phenotype patients and tailor prescriptions beyond trial populations.

INSIGHT

Make Guidelines Living Documents

Guidelines should evolve into living documents with continuous updates to reflect rapid advances in cardiology.
Continuous updates are needed so clinicians know quickly when new tools, devices, or drugs are effective or when treatments should not be used.

ADVICE

Embed Guidelines Into The Electronic Health Record

Integrate guideline decision support directly into clinical workflows like EHRs to improve implementation.
Use tools (ESC chat, co-pilots) that let clinicians query a patient's data and get actionable suggestions at the point of care.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

This episode covers:

Cardiology this Week: A concise summary of recent studies
The future of guidelines in an era of big data and AI
Exercise in hypertrophic cardiomyopathy
Snapshots

Host: Sabiha Gati

Guests: Kostas Koskinas, Thomas F. Luescher, Michael Papadakis, Stephan Achenbach

Want to watch that episode? Go to: https://esc365.escardio.org/event/2556

Want to watch the extended interview on The future of guidelines in an era of Big Data and AI, go to: https://esc365.escardio.org/event/2556?resource=interview

Disclaimer:

ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner.

This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.

Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.

All declarations of interest are listed at the end of the episode.

The ESC is not liable for any translated content of this video. The English language always prevails.

Declarations of interests:

Stephan Achenbach, Yasmina Bououdina, Sabiha Gati, Nicolle Kraenkel and Thomas F. Luescher have declared to have no potential conflicts of interest to report.

Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI.

Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo.

Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.

Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck.

Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.

Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.